EMA Recommends Rasonque's Authorisation for Metastatic Pancreatic Cancer
EMA recommends authorisation of Rasonque for metastatic pancreatic cancer following a phased data review under its Cancer Medicines Pathfinder project.
Pancreatic Adenocarcinoma | 19/10/2026 | By News Bureau
Partner Therapeutics Wins FDA Approval for BIZENGRI in NRG1+ Cholangiocarcinoma
Partner Therapeutics receives US Food and Drug Administration (FDA) approval for BIZENGRI, the first targeted therapy for NRG1 fusion-positive cholangiocarcinoma, expanding use across NSCLC and pancreatic cancer.
Pancreatic Adenocarcinoma | 12/05/2026 | By News Bureau | 245
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy